New study peers into diabetic eyes to see how popular drugs impact vision

NCT ID NCT07536516

Recruiting now Knowledge-focused Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how certain diabetes medications (semaglutide, liraglutide, and tirzepatide) affect blood flow and oxygen use in the eyes of people with diabetes. Researchers will use special cameras to measure eye blood vessels and oxygen levels in 20 adults before and after starting these drugs. The goal is to learn more about how these treatments might influence eye health, especially diabetic retinopathy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 receptor agonists (semaglutide, liraglutide) and GIP/GLP-1 dual agonist (tirzepatide)
What this could lead to: If successful, this could help doctors understand how common diabetes drugs affect eye health, potentially guiding safer treatment choices.
What could go wrong: This is a small, early observational study with only 20 participants. It measures eye changes but does not test whether the drugs cause harm or benefit directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS

Contacts and locations

Locations

Medical University Vienna
RECRUITING

Vienna, State of Vienna, 1090, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.